Drug Shortage Report for CEFTRIAXONE FOR INJECTION
Report ID | 158762 |
Drug Identification Number | 02409968 |
Brand name | CEFTRIAXONE FOR INJECTION |
Common or Proper name | CefTRIAXone for Injection |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | CEFTRIAXONE |
Strength(s) | 100G |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 100 g |
ATC code | J01DD |
ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | |
Actual start date | 2022-02-01 |
Estimated end date | 2022-04-30 |
Actual end date | 2022-04-30 |
Shortage status | Resolved |
Updated date | 2022-05-02 |
Company comments | . |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2022-05-02 | French | Compare |
v3 | 2022-05-02 | English | Compare |
v2 | 2022-04-13 | French | Compare |
v1 | 2022-04-13 | English | Compare |
Showing 1 to 4 of 4